Fremanezumab linked to fewer monthly migraine days

May 16, 2018

(HealthDay)—For patients with episodic migraine, fremanezumab is associated with a reduction in the mean number of monthly migraine days, according to a study published in the May 15 issue of the Journal of the American Medical Association.

David W. Dodick, M.D., from Mayo Clinic Arizona in Phoenix, and colleagues conducted a at 123 sites in nine countries. Participants, aged 18 to 70 years with episodic , were randomized to receive subcutaneous monthly dosing of fremanezumab (290 participants, 225 mg at baseline and weeks four and eight), a single higher dose of fremanezumab (291 patients, 675 mg at baseline, placebo at weeks four and eight), or placebo (294 participants); 90.4 percent of participants completed the trial.

The researchers found that over 12 weeks, mean migraine days per month decreased from 8.9 to 4.9 days, from 9.2 to 5.3 days, and from 9.1 to 6.5 days in the fremanezumab monthly dosing group, the fremanezumab single-higher-dose group, and the , respectively. The difference with monthly dosing and single dosing versus was −1.5 and −1.3 days, respectively. Injection site erythema, injection site induration, diarrhea, anxiety, and depression were the most common adverse events that led to discontinuation.

"Further research is needed to assess effectiveness against other preventive medications," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Teva Pharmaceuticals, which manufactures fremanezumab and funded the study.

Explore further: When others fail, new migraine treatment may work

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

When others fail, new migraine treatment may work

April 17, 2018
People who have tried unsuccessfully to prevent migraine with other treatments may find relief with a drug called erenumab, according to a preliminary study released today that will be presented at the American Academy of ...

Several new medications in the pipeline to prevent migraine

June 13, 2017
(HealthDay)—A host of new medications that appear to prevent migraine headaches are in the final stages of testing and approval in the United States, according to a presentation at the annual meeting of the American Headache ...

New drug to prevent migraine may start working in days

June 8, 2016
A new drug to prevent migraine was associated with fewer headache hours for people with chronic migraine within three to seven days after the first injection, according to a study published in the June 8, 2016, online issue ...

Cannabidiol efficacious for lennox-gastaut drop seizures

January 26, 2018
(HealthDay)—For patients with drop seizures associated with Lennox-Gastaut syndrome, add-on cannabidiol is associated with a reduction in monthly drop seizure frequency, according to a study published online Jan. 24 in ...

New, long-acting drugs cut frequency of migraine headaches

November 30, 2017
New, long-acting drugs may hold hope for millions of people who often suffer migraines. Studies of two of these medicines, given as shots every month or so, found they cut the frequency of the notoriously painful and disabling ...

Five-day nitrofurantoin beats single-dose fosfomycin for UTI

April 25, 2018
(HealthDay)—Five-day nitrofurantoin is associated with increased likelihood of clinical and microbiological resolution compared with single-dose fosfomycin among women with lower urinary tract infection (UTI), according ...

Recommended for you

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

Fighting a deadly parasite: Scientists devise a method to store Cryptosporidium, aiding vaccine research efforts

September 21, 2018
In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. ...

Scientists make significant discovery in the fight against drug-resistant tuberculosis

September 20, 2018
A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis.

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.